• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Medtronic touts therapy delivered via SynchroMed pump in patients with post-stroke spasticity

January 11, 2018 By Sarah Faulkner

MedtronicMedtronic (NYSE:MDT)  touted data today showing that intrathecal baclofen therapy delivered via the company’s SychroMed II infusion pump performed better than the conventional treatment for patients with severe post-stroke spasticity.

The medtech titan’s SynchroMed II pump is the only device approved in the U.S. for ITB therapy.

The Sisters study pitted Medtronic’s ITB therapy against oral antispastic medications for the treatment of post-stroke spasticity. The trial’s primary outcome was change in muscle tone and spastic hypertonia from baseline to six months.

Researchers found that ITB therapy demonstrated a significant improvement over oral drugs in reducing muscle tone in the affected lower and upper extremities, according to Medtronic. The group of patients who received ITB therapy saw improvement to their total functional improvement scores after six months, while patients in the comparison arm saw their scores worsen.

24 out of 25 patients in the ITB group reported adverse events, compared to 22 out of 35 patients in the control arm. Events were generally consistent with the known safety profile of ITB therapy, Medtronic noted, and no patient stopped treatment due to adverse events.

“ITB Therapy is underused when it comes to treating severe spasticity in post-stroke patients,” lead author and study investigator Michael Creamer said in prepared remarks. “The study results demonstrate that ITB Therapy is superior to oral medications in decreasing muscle tone.”

“All over the world, PSS patients are suffering from inadequately managed severe spasticity that can interfere with their quality of life,” Charlie Covert, VP and GM of Medtronic’s, targeted drug delivery division, added. “At Medtronic, we’re committed to raising awareness of ITB Therapy as an effective treatment for severe PSS and to ensure it is available to the patients who need it most.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Neurological, Pharmaceuticals, Wall Street Beat Tagged With: Medtronic

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS